When can an off-label drug be the appropriate comparator therapy?
This question was discussed at the recent G-BA meeting on 2 September 2021. Previously, the G-BA had decided on the following procedural
Category: News and updates
G-BA assesses method of allogeneic SCT in ALL, AML and NHL
Did you know that some hospital methods are not covered by SHI funds? In Germany, non-drug interventions are assessed as methods. Methods
The process of method assessments in Germany
The G-BA, physicians, hospitals, SHI funds or patient organizations can request the assessment of a new method. If the request was accepted,
New rapid report by IQWiG
The IQWiG not only examines the benefits and harms of medical interventions for early benefit assessments but also produces independent, evidence-based reports
Negotiated reimbursement price applicable 12 months after launch
